US 11,713,324 B2
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Graham Beaton, Poway, CA (US); Mi Chen, San Diego, CA (US); Timothy Richard Coon, Carlsbad, CA (US); Todd Ewing, San Diego, CA (US); Wanlong Jiang, San Diego, CA (US); Willy Moree, San Diego, CA (US); Martin Rowbottom, San Diego, CA (US); Warren Wade, San Diego, CA (US); Liren Zhao, San Diego, CA (US); Richard Lowe, Oakland, CA (US); Nicole Smith, San Diego, CA (US); Neil Ashweek, San Diego, CA (US); and Yun-Fei Zhu, San Diego, CA (US)
Assigned to Neurocrine Biosciences, Inc., San Diego, CA (US)
Filed by Neurocrine Biosciences, Inc., San Diego, CA (US)
Filed on Dec. 18, 2020, as Appl. No. 17/126,581.
Application 13/293,943 is a division of application No. 12/594,809, granted, now 8,084,614, issued on Dec. 27, 2011, previously published as PCT/US2008/059438, filed on Apr. 4, 2008.
Application 17/126,581 is a continuation of application No. 16/460,781, filed on Jul. 2, 2019, granted, now 10,941,159.
Application 16/460,781 is a continuation of application No. 15/445,673, filed on Feb. 28, 2017, granted, now 10,336,769, issued on Jul. 2, 2019.
Application 15/445,673 is a continuation of application No. 15/210,470, filed on Jul. 14, 2016, abandoned.
Application 15/210,470 is a continuation of application No. 14/592,690, filed on Jan. 8, 2015, granted, now 9,422,310, issued on Aug. 23, 2016.
Application 14/592,690 is a continuation of application No. 13/910,961, filed on Jun. 5, 2013, granted, now 8,952,161, issued on Feb. 10, 2015.
Application 13/910,961 is a continuation of application No. 13/293,943, filed on Nov. 10, 2011, granted, now 8,481,738, issued on Jul. 9, 2013.
Claims priority of provisional application 60/910,621, filed on Apr. 6, 2007.
Prior Publication US 2021/0284653 A1, Sep. 16, 2021
Int. Cl. C07D 495/04 (2006.01); C07C 233/88 (2006.01); C07C 235/42 (2006.01); C07C 255/57 (2006.01); C07D 213/56 (2006.01); C07D 213/61 (2006.01); C07D 213/64 (2006.01); C07D 213/70 (2006.01); C07D 213/81 (2006.01); C07D 213/84 (2006.01); C07D 213/89 (2006.01); C07D 215/14 (2006.01); C07D 215/54 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 239/36 (2006.01); C07D 213/58 (2006.01)
CPC C07D 495/04 (2013.01) [C07C 233/88 (2013.01); C07C 235/42 (2013.01); C07C 255/57 (2013.01); C07D 213/56 (2013.01); C07D 213/58 (2013.01); C07D 213/61 (2013.01); C07D 213/64 (2013.01); C07D 213/70 (2013.01); C07D 213/81 (2013.01); C07D 213/84 (2013.01); C07D 213/89 (2013.01); C07D 215/14 (2013.01); C07D 215/54 (2013.01); C07D 239/36 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01)] 2 Claims
 
1. A process for preparing 3-(2-{[4-chloro-3-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-benzoyl]-methyl-amino}-phenoxy)-propionic acid, comprising:
contacting a solution of 4-chloro-3-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-N-[2-(3-hydroxy-propoxy)-phenyl]-N-methyl-benzamide with a solution of sodium periodate, followed by ruthenium (III) chloride, and
isolating the 3-(2-[4-chloro-3-(4-cyano-6-trifluoromethyl-pyridin-3-yl)-benzoyl]-methyl-amino}-phenoxy)-propionic acid.